We are live on ! Find out more

Royalty Pharma

RPRX

Market cap $24.8B

378 hedge funds and large institutions have $9.24B invested in Royalty Pharma in 2024 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 161 increasing their positions, 113 reducing their positions, and 48 closing their positions.

New

Increased

Maintained

Reduced

Closed

43% more call options, than puts

Call options by funds: $15.3M | Put options by funds: $10.7M

42% more repeat investments, than reductions

Existing positions increased: 161 | Existing positions reduced: 113

35% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 48

4% more funds holding

Funds holding: 363 → 378 (+15)

8% less capital invested

Capital invested by funds: $10B → $9.24B (-$805M)

11.89% less ownership

Funds ownership: 80.04% → 68.15% (-12%)

13% less funds holding in top 10

Funds holding in top 10: 8 → 7 (-1)

Holders

378

Holders Change

+15

Holders Change %

+4.13%

% of All Funds

5.45%

Holding in Top 10

Holding in Top 10 Change

-1

Holding in Top 10 Change %

-12.5%

% of All Funds

0.1%

New

Increased

161

Reduced

113

Closed

Calls

$15.3M

Puts

$10.7M

Net Calls

+$4.62M

Net Calls Change

-$3.44M

Top Buyers

1	Millennium Management New York	+$90M
2	Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada	+$78.4M
3	Fidelity Investments Boston, Massachusetts	+$60.4M
4	NSCM New South Capital Management Memphis, Tennessee	+$43.1M
5	Viking Global Investors Stamford, Connecticut	+$41.2M

Top Sellers

1	Morgan Stanley New York	-$1.43B
2	Swedbank Stockholm, Sweden	-$154M
3	Man Group London, United Kingdom	-$70.2M
4	Goldman Sachs New York	-$66.8M
5	SCM Suvretta Capital Management New York	-$48.3M